|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found SPARC overexpressed mainly in lung metastases from melanoma.
|
24993904 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
|
22911700 |
2012 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we show that overexpression of SPARC renders cells more resistant to the p53-mediated cytotoxic effects of the DNA-damaging drug actinomycin-D. Our study indicates that SPARC functions through activation of Akt and MDM2 to limit p53 levels and that acquired expression of SPARC during melanoma development would confer survival advantages through suppression of p53-dependent apoptotic pathways.
|
21685937 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we used siRNA and conditional shRNA to investigate the contribution of tumor-derived SPARC to melanoma cell growth in vitro and in vivo.
|
20955243 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To validate the potential of SPARC as a therapeutic target, we examined the effect of the knockdown of SPARC with SPARC-specific siRNA on the growth of human melanoma cell lines.
|
20100207 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor.
|
18849185 |
2008 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This was not a general resistance to growth suppressing agents, as melanoma cells with restricted SPARC expression were more resistant to chemotherapeutic agents.
|
18059024 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, downregulation of SPARC levels in melanoma cells using either an antisense RNA or a shRNA against SPARC sensitized them to hMel-SPARC addition in proliferation and migration assays, suggesting that malignant cells developed a SPARC-resistance mechanism.
|
18059024 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
(2007) begin to answer this question by demonstrating that SPARC produced by melanoma, but not stromal cells, is essential to regulate melanoma cell growth.
|
17934501 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells.
|
17994631 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate a central role for Osteonectin in the regulation of gene expression changes driving the progression of melanoma toward metastasis.
|
17724718 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All the data indicate that melanoma growth is not subject to regulation by exogenous SPARC, nor by stromal organization, but only by SPARC levels produced by the malignant cells themselves.
|
17625595 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
These results indicate a central role for Osteonectin in the regulation of gene expression changes driving the progression of melanoma toward metastasis.
|
17724718 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have shown that expression of the herpes simplex virus-thymidine kinase (TK) gene driven by the SPARC promoter in combination with ganciclovir inhibited human melanoma cell growth in monolayer as well as in multicellular spheroids.
|
17041094 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Concurrent with these changes, SPARC expression stimulates melanocyte motility and melanoma cell invasion.
|
16885349 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.
|
15958556 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum SPARC concentrations in melanoma patients were greater than those in healthy donors (P = 0.001).
|
16299239 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of osteonectin was confirmed by Northern and Western blot analysis and immunohistochemistry and correlated in organotypic cultures with the beta(3)-induced progression from RGP to VGP melanoma.
|
11782382 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Osteonectin expression was not blocked when melanoma cells were cultured with anti-alpha(v)beta(3) LM609 mAb, mitogen-activated protein kinase, or protein kinase C inhibitors, indicating that other signaling pathway(s) operate through alpha(v)beta(3) integrin during conversion from RGP to VGP.
|
11782382 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis showed that SPARC was strongly expressed in 100% of primary melanomas (7 of 7) and metastatic melanomas (29 of 29), moderately expressed in most of the positive dysplastic nevi (13 of 14), and only weakly expressed in nevocellular nevi (4 of 25).
|
9008236 |
1997 |